Epilepsy, Tonic-Clonic clinical trials
The registry lists 23 studies for Epilepsy, Tonic-Clonic across more than 10 countries. 3 are recruiting or about to start. 10 of them are mainly about Epilepsy, Tonic-Clonic (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-03.
Get an email when these change. Save the Epilepsy, Tonic-Clonic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · GlaxoSmithKline (3) · LivaNova (2) · Affiliated Hospital of Nantong University (1) · cerbomed GmbH (1) · UCB Pharma SA (1) · Neuroelectrics Corporation (1) · Zogenix, Inc. (1)
What is being tested here
Drugs under test in Epilepsy, Tonic-Clonic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Levetiracetam | 1 | 3 | 4 |
| Topiramate | 0 | 3 | 3 |
| Lamotrigine | 0 | 1 | 2 |
| Fenfluramine | 0 | 1 | 1 |
| Fosphenytoin | 0 | 0 | 1 |
| Phenytoin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Nov 2027A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. · Phase 3 · Zogenix, Inc.
- Jul 2027A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures · Affiliated Hospital of Nantong University
Who these studies take
Of the 2 Epilepsy, Tonic-Clonic studies recruiting now, 1 (50%) set no upper age limit and 1 (50%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 0 (0%) | 0 (0%) |
| 30 | 0 (0%) | 0 (0%) |
| 40 | 1 (50%) | 1 (50%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 1 (50%) | 1 (50%) |
| 85 | 1 (50%) | 1 (50%) |
Across all 23 studies, recruiting or not: 22% stop at 75 or younger and 17% at 65; 70% take children; 0% are for women only and 4% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 23 of 23. search them.
- Clinical Trial of Vormatrigine in Adult Patients With EpilepsyEnrolling by invitationNCT07287163Phase 36 countries
- LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down SyndromeRecruitingNCT07234695Phase 31 country
- A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic SeizuresRecruitingNCT06967012Phase 41 country
- RNS System NAUTILUS StudyCompletedNCT05147571Not applicable1 country
- A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.Active, not recruitingNCT05064878Phase 314 countries
- Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal EpilepsyCompletedNCT04770337Not applicable4 countries
- EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring SystemCompletedNCT05059002Not applicable1 country
- Novel Helmet Design in Patients With SeizuresCompletedNCT03443388Not applicable1 country
- A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized EpilepsyCompletedNCT042528467 countries
- Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility StudyCompletedNCT03446664Not applicable2 countries
- Embrace and Quality of LifeTerminatedNCT03831802Not applicable1 country
- XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)WithdrawnNCT042826811 country
- Evaluation and Treatment of Patients With EpilepsyTerminatedNCT000138451 country
- Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.CompletedNCT00150813Phase 34 countries
- Topiramate Bioequivalence Study Brazil - FastCompletedNCT01439438Phase 11 country
- Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New DrugCompletedNCT00043901Phase 44 countries
- Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) SeizuresCompletedNCT00104416Phase 311 countries
- IV Keppra in the Emergency Department for Prevention of Early Recurrent SeizuresCompletedNCT00510783Phase 41 country
- Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.CompletedNCT00150787Phase 3
- A Study of the Efficacy and Safety of Topiramate as "Add on" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic SeizuresCompletedNCT00236704Phase 3
- A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic SeizuresCompletedNCT00236418Phase 3
- A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent EpilepsyCompletedNCT00231556Phase 3
- Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat EpilepsyCompletedNCT01178437Not applicable1 country